Why Is Pasithea Therapeutics (KTTA) Stock Down 12% Today?

Advertisement

  • Pasithea Therapeutics (KTTA) stock is down Wednesday after recent volatility.
  • The company’s shares soared more than 100% on Tuesday but closed out the day largely unchanged.
  • That came about after posting results from preclinical trials.
KTTA Stock - Why Is Pasithea Therapeutics (KTTA) Stock Down 12% Today?

Source: Shutterstock / PopTika

Pasithea Therapeutics (NASDAQ:KTTA) stock is falling on Wednesday after the company’s shares experienced major volatility on Tuesday.

Investors watching KTTA stock will note that it closed out Tuesday up less than 1%. However, in earlier trading that day, the stock saw gains of more than 100%.

So what happened?

Pasithea Therapeutics saw its shares rally in early morning trading on Tuesday alongside results from two preclinical trials. That came with heavy trading pushing the shares higher. However, it was unable to maintain that increased price.

It’s possible that this has to do with KTTA being a penny stock. That opens it up to vulnerabilities, such as extreme volatility. It could be that day traders latched onto the stock yesterday alongside the study news and then sold their shares when prices peaked.

KTTA Stock Movement on Wednesday

As for KTTA stock movement today, the company’s shares are down 11.8% during pre-market trading on Wednesday. That comes as some 31,000 shares change hands, as compared to its daily average of about 1.7 million shares.

Investors seeking out even more of the most recent stock market stories will want to stick around!

We have all of the hottest stock market news worth reading about on Wednesday! That includes everything happening with shares of Loop Media (NYSEMKT:LPTV) stock, Innovative International (NASDAQ:IOAC) stock and RiskOn International (NASDAQ:ROI) stock this morning. All of that news is available at the following links!

More Stock Market News for Wednesday

On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks. 

Read More: Penny Stocks — How to Profit Without Getting Scammed 

On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.


Article printed from InvestorPlace Media, https://investorplace.com/2023/12/why-is-pasithea-therapeutics-ktta-stock-down-12-today/.

©2024 InvestorPlace Media, LLC